ADAs to alemtuzumab
Research type
Research Study
Full title
Impact of anti-drug antibodies to alemtuzumab in multiple sclerosis
IRAS ID
304993
Contact name
Sharmilee Gnanapavan
Contact email
Sponsor organisation
Barts Health NHS Trust
Clinicaltrials.gov Identifier
N/A, N/A
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
One of the treatments for Multiple Sclerosis (MS) called alemtuzumab has been shown to be good at reducing the flares in MS.
Sometimes, our own bodies react differently to drugs than expected, making them less effective and predictable. This does not happen that frequently, but it is important that we understand what is happening and why by learning more about the reasons. In some circumstances, the body may make something called anti-drug antibodies (ADA’s), and this study is investigating how and when this may happen.
REC name
North East - Newcastle & North Tyneside 2 Research Ethics Committee
REC reference
22/NE/0029
Date of REC Opinion
10 Mar 2022
REC opinion
Further Information Favourable Opinion